Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2020-10-20Clinical Trial Update: Connected Healthcare for Individuals Living at Home With Chronic Conditions [NA]
Clinical trial update describing connected healthcare for home-based management of chronic conditions; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression [Phase 2]
Phase 2 study in Japanese participants evaluated fixed-dose intranasal esketamine for treatment-resistant depression; the trial completed an…
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Adjunct Minocyline in Treatment-resistant Depression [Phase 2]
Phase 2 clinical trial investigating adjunct minocycline for treatment-resistant major depressive disorder has completed.
-
CLINICAL_TRIALS withdrawal · 2020-10-19Clinical Trial Update: Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion [Phase 4]
Phase 4 trial exploring EEG-based prediction for antidepressant response with duloxetine and bupropion was withdrawn.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Anxiety and Depression in Epilepsy: A Treatment Study [Phase 4]
Phase 4 clinical trial examining treatment for anxiety and depression in patients with epilepsy has completed with posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Development and Pilot Trial of an Intervention to Reduce Disclosure Recipients Negative Social Reactions and Victims Psychological Distress and Problem Drinking [NA]
A pilot trial evaluating an intervention aimed at reducing negative social reactions to disclosure and associated psychological distress and…
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder [Phase 2]
Phase 2 trial investigating prevention of comorbid depression and obesity in adults with ADHD; completed.
-
CLINICAL_TRIALS withdrawal · 2020-10-19Clinical Trial Update: Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram [Phase 4]
Phase 4 clinical trial investigating EEG-based prediction for antidepressant response to sertraline and escitalopram has been withdrawn.
-
FDA approval · 2020-10-16FDA Approved: BUPROPION HYDROCHLORIDE XL — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for BUPROPION HYDROCHLORIDE XL by Actavis Pharma, Inc. under the ANDA process for the extended-relea…
-
CLINICAL_TRIALS trial_result · 2020-10-14Clinical Trial Update: eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients [Phase 2]
Phase 2 trial update for eIMPACT evaluating modernized collaborative care to reduce excess cardiovascular risk in older patients with depres…
-
CLINICAL_TRIALS research · 2020-10-14Clinical Trial Update: Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder [Phase 4]
Phase 4 trial evaluating cost-effectiveness and quality of life in major depressive disorder has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-10-09Clinical Trial Update: Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) [Phase 3]
Phase 3 trial of rapastinel monotherapy in major depressive disorder was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-10-08Clinical Trial Update: IntelliCare in College Students [NA]
A completed clinical trial on IntelliCare for depression and anxiety in college students with results posted.
-
FDA approval · 2020-10-07FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for bupropion hydrochloride from Actavis Pharma, Inc., indicating an approved change to the gene…
-
CLINICAL_TRIALS trial_result · 2020-10-06Clinical Trial Update: Emotional and Cognitive Control in Late-Onset Depression [Phase 4]
Phase 4 trial update for emotional and cognitive control in late-onset depression completed with results posted.
-
FDA approval · 2020-10-01FDA Approved: CYMBALTA — Supplemental Application (Eli Lilly and Company)
FDA approves a supplemental application for Cymbalta (duloxetine hydrochloride) submitted by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2020-09-29Clinical Trial Update: A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder [Phase 2]
A Phase II study evaluated the safety and efficacy of PDC-1421 capsules in patients with Major Depressive Disorder; the trial is completed w…
-
CLINICAL_TRIALS trial_result · 2020-09-29Clinical Trial Update: The Modular Protocol for Mental Health (MPMH) [Phase 1, Phase 2]
Phase 1 and Phase 2 study of the Modular Protocol for Mental Health (MPMH) completed; investigates treatment approaches for multiple mental …
-
FDA approval · 2020-09-28FDA Approved: BUPROPION HYDROCHLORIDE SR — Supplemental Application (Slate Run Pharmaceuticals, LLC)
FDA approves a supplemental application for Bupropion Hydrochloride Sustained-Release, submitted by Slate Run Pharmaceuticals, LLC.
-
CLINICAL_TRIALS trial_result · 2020-09-25Clinical Trial Update: 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide [Phase 3]
Phase 3 trial evaluating intranasal esketamine added to standard of care for rapid reduction of symptoms in adults with major depressive dis…
-
FDA label_change · 2020-09-25FDA Approved: MIRTAZAPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for mirtazapine from Sun Pharmaceutical Industries, resulting in labeling updates.
-
CLINICAL_TRIALS trial_result · 2020-09-22Clinical Trial Update: IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV [NA]
Trial update for IMPAACT 2002 evaluating cognitive behavioral therapy plus medication management for depression in youth with HIV; study com…
-
CLINICAL_TRIALS trial_result · 2020-09-21Clinical Trial Update: Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3) [NA]
Clinical trial update for transcranial laser therapy in major depressive disorder; status completed with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-09-14Clinical Trial Update: Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a behavioral intervention for low-income individuals with depression who are cigarette smokers and in …
-
CLINICAL_TRIALS trial_result · 2020-09-11Clinical Trial Update: A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Pilot [NA]
Completed pragmatic trial evaluating a policy-relevant US trauma care system for PTSD and comorbidity; results posted in 2020.